ABG
ITOS

Ally Bridge Group’s iTeos Therapeutics ITOS Stock Holding History

Ally Bridge Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-322,794
Closed -$11M – 34
2021
Q1 		$11M Hold
322,794
– – 2.12% 14
2020
Q4 		$10.9M Buy
+322,794
New +$8.55M 1.87% 18

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ally Bridge Group's ITOS Position: Q2 2021 in Review

Ally Bridge Group sold out of iTeos Therapeutics (ITOS) in Q2 2021, closing a stake of 322,794 shares — an estimated $11M sold.

Ally Bridge Group first reported a position in ITOS in Q4 2020 and held it in 2 quarters. The position peaked at $11M in Q1 2021. 83 funds tracked by Wall St. Rank hold ITOS as of Q2 2021.

  • Ally Bridge Group reported no remaining iTeos Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ally Bridge Group sold 322,794 iTeos Therapeutics shares in Q2 2021, an estimated $11M.
  • Ally Bridge Group first reported a position in iTeos Therapeutics in Q4 2020 and held it in 2 quarters.
  • Ally Bridge Group's iTeos Therapeutics position peaked at $11M in Q1 2021.
  • 83 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2021.

Based on Ally Bridge Group's 13F filing for Q2 2021, filed 16 Aug 2021.